Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: To evaluate the influence of retinal angiomatous proliferation (RAP) stage on visual and anatomic outcome after ranibizumab (Lucentis®).
Methods: This was a prospective study on consecutively diagnosed RAP eyes at the Hospital Clínico San Carlos, Madrid. Best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) are performed monthly. Indocyanine green angiography (ICG) and fluorescein angiography (FA) are performed at baseline and every 3 months thereafter. A starting dose of a monthly ranibizumab injection in the first 3 months is followed by retreatment in case of intraretinal edema, subretinal fluid, or pigment epithelium detachment (PED) in OCT, increased leakage in FA, or a hot spot in ICG.
Results: A total of 53 eyes from 49 patients were included. The mean change in BCVA at 12 months was +7.3, +0.83, and -2.1 letters in stages IIA (21 cases), II B (18 cases), and III (14 cases), respectively. After adjusting the change in BCVA according to baseline BCVA, ß coefficient was -6.012 letters (p=0.025) in stage IIB and -9.762 letters (p=0.003) in stage III vs stage IIA. Four cases had a retinal pigment epithelium tear after injection of ranibizumab.
Conclusions: Patients in stage II without PED have a better visual and anatomic evolution than patients in stage II with PED and stage III.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5301/EJO.2011.6526 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-term remission and incidence of recurrence of neovascularization in intravitreal injection treated exudative age-related macular degeneration.
Graefes Arch Clin Exp Ophthalmol
July 2025
Department of Ophthalmology, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
Purpose: This study evaluates the long-term remission (LTR) rate, recurrence rate, and prognostic factors of extended remission and recurrence in macular neovascularization (MNV) eyes treated with aflibercept.
Methods: This was a retrospective cohort of treatment-naïve MNV eyes treated in Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan with intravitreal aflibercept between 2015 and 2023. Patients followed pro re nata (PRN) or Treat-and-Extend (T&E) protocols.
Outcomes of Treat-and-Extend using Aflibercept in Type 3 Macular Neovascularization: A Prospective Clinical Trial.
Retina
June 2025
Department of Ophthalmology, Kim's Eye Hospital, Seoul, South Korea.
Purpose: To evaluate the clinical outcomes of a treat-and-extend(TAE) regimen using aflibercept for type 3 macular neovascularization(MNV).
Methods: In this prospective phase 4 clinical trial, 25 patients with type 3 MNV underwent TAE with aflibercept for over 76 weeks. Following an initial three loading injections, the interval between injections was extended by 2 weeks, up to a maximum of 16 weeks, provided there was no recurrence.
Factors determining timing of first recurrence after three loading aflibercept injections in newly diagnosed neovascular age-related macular degeneration.
Jpn J Ophthalmol
June 2025
Department of Ophthalmology, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Gyeonggi-Do, Korea. 271, Cheon Bo-ro, Uijeongbu, Gyeonggi-Do, 11765, Republic of Korea.
Purpose: To investigate factors affecting timing of the first recurrence after three loading aflibercept injections in patients with newly diagnosed neovascular age-related macular degeneration (NAMD).
Study Design: Retrospective chart review.
Methods: A retrospective study was conducted on 193 eyes from 193 patients newly diagnosed with NAMD who received monthly three loading aflibercept injections and a fourth injection by pro-re-nata therapy regimen for recurrence between January 2016 and May 2023.
Retinal angiomatous proliferation and pachychoroid.
Arch Soc Esp Oftalmol (Engl Ed)
September 2025
Servicio de Oftalmología, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
The association between retinal angiomatous proliferation (RAP) or type 3 choroidal neovascular membrane (CNV) and pachychoroidopathy has been rarely described. Its occurrence would be a consequence of ischemia resulting from loss of the choriocapillaris secondary to compression of the pachyvessels. We report a case of retinal angiomatous proliferation in the context of pachychoroidopathy.
View Article and Find Full Text PDFLong-term outcomes and the association between early detection of retinal pigment epithelial atrophy and remission after loading dose in eyes with retinal angiomatous proliferation.
Jpn J Ophthalmol
July 2025
Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, Shimokato 1110, Chuo, Yamanashi, 409-3821, Japan.
Purpose: To investigate the association between early detection of retinal pigment epithelial (RPE) atrophy after anti-vascular endothelial growth factor (VEGF) treatment and the long-term treatment outcomes in eyes with retinal angiomatous proliferation (RAP).
Study Design: A retrospective observational study METHODS: All patients with treatment-naive RAP initially received three monthly anti-VEGF administration with or without photodynamic therapy (PDT), followed by as-needed anti-VEGF administration. At 12 months post-injection, they were divided into two groups depending on the presence or absence of RPE atrophy.